Page 43 - 台灣肝癌醫學冬季會手冊-1222-V3_Neat

Changing paradigm of treatment strategy from

intermediate to advanced stage in HCC

Ching-Wei Chang, M.D., Ph.D.

Division of Gastroenterology, Department of Medicine, MacKay Memorial Hospital,

Taipei, Taiwan.

Lenvatinib is a multi-target tyrosine kinase inhibitor (TKI) and an emerging first-line

hepatocellu lenvatinib has anti-

tumor proliferation and immunomodulatory activities in preclinical studies.

III pro patients with advanced HCC. In comparison,
lenvatinib was non-inferior to sorafenib in overall survival (OS), and even shows superiority with

regard to all the secondary efficacy endpoints. In real-world studies, lenvatinib was found to be well

tolerated and effective in more heterogeneous HCC patient populations.

multin intermediate-s exceeding

the up-to-seven criteria with Child-Pugh A liver function, who usually do not benefit from TACE,

lenvatinib provides a more favorable outcome than TACE. Immune checkpoint inhibitors

ou been the
and IC broader prospects for HCC. Further research is

required for confirming ideal treatment strategies, the effectiveness, and the safety of the expanded

indication of lenvatinib.